RVMD Unusual Options Activity — 2026-03-17

🧬 RVMD Just Got a $2.8M Call Bet - Someone Knows the RASolute 302 Clock Is Ticking! 🔥

📅 March 17, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just loaded up $2.8 MILLION on RVMD $105 calls expiring April 17 - right as the biotech world holds its breath for the most anticipated Phase 3 data readout in oncology this year. This isn't a casual trade: 5,000 contracts on an option with only 138 prior open interest means this is nearly all fresh positioning, not someone rolling an existing bet. With Revolution Medicines' RASolute 302 trial top-line data expected in H1 2026 and the stock sitting just 5% below the $105 strike, this is a high-conviction bet that the Phase 3 catalyst drops BEFORE April 17th expiration.

---

📊 Company Overview

Revolution Medicines (RVMD) is a clinical-stage oncology company pioneering a category of drugs that nobody else has gotten to Phase 3 yet:

• Market Cap: $19.6 Billion (pre-revenue biotech)
• Industry: Biological Products
• What They Do: RVMD is developing RAS(ON) multi-selective inhibitors - drugs that can block multiple RAS gene mutations simultaneously. Think of RAS mutations as the engine driving roughly 30% of all human cancers. While competitors like Amgen's sotorasib can only hit the KRAS G12C mutation (a small slice of patients), RVMD's daraxonrasib targets G12X, G13X, and Q61X - covering roughly 85% of RAS-driven pancreatic cancer patients.
• Cash Runway: $2.03B in cash + $1.75B committed from Royalty Pharma
• Current Price: ~$100.00 | 52-Week Range: $29.17 - $124.49

---

💰 The Option Flow Breakdown

The Tape (March 17, 2026 @ 13:23:08):

🤓 What This Actually Means

This trade screams BTO (Buy To Open) Long Call - fresh bullish positioning, not a hedge.

• 💸 $2.8M premium at mid: Paying $8.00/contract on 5,000 contracts = 500,000 shares worth of exposure
• 📊 Volume vs OI tells the story: 5,000 contracts vs only 138 prior OI = 36x the existing open interest. Nearly all of this is new money entering a position
• 🎯 Strike selection is deliberate: The $105 strike sits exactly at a key gamma resistance level. This trader is betting on a clean breakout
• ⏰ 31-day window: April 17 expiration gives just enough time to capture a Phase 3 data readout expected "imminently" in H1 2026
• 🐋 Size context: The 3,500-lot single print at mid-market is not a retail order. This is institutional conviction

Translation for regular folks:

Someone paid $2.8M betting RVMD stock will be above $113 (breakeven) by April 17. They need a 13% move in 31 days. With a binary Phase 3 catalyst that could arrive any day, this is a calculated bet that the data is coming SOON - and that it's good.

Unusual Score: 🔥 HIGH - Volume-to-OI ratio of 36x puts this in rare territory for RVMD. Trades of this size relative to existing open interest happen only a handful of times a year on any individual biotech name. This isn't someone adding to an existing position - this is a fresh, concentrated bet.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

RVMD has been on a wild ride in 2026 - with a 52-week range stretching from $29.17 all the way to $124.49. The stock catapulted from sub-$50 levels in mid-2025 on the back of Merck acquisition speculation, then crater-crashed 20% in a single day when Merck walked away from acquisition talks on January 23, sending shares from ~$117 down to ~$95. Currently hovering near $100, the stock is trying to regain footing above its 50-day moving average ($102.88) while the 200-day MA ($75.23) shows just how far it's come from the dark days.

Key observations:

• 📉 Post-Merck drop is the setup: Shares gave back M&A premium but the clinical story hasn't changed. This creates the asymmetric entry opportunity the option buyer is exploiting
• 📊 Consolidation zone: Trading $95-$105 for 7+ weeks - a coiled spring waiting for the data catalyst
• ⚠️ Below 50-day MA ($102.88): Stock needs to reclaim $102-$103 to confirm bullish momentum
• 🎯 $100 psychological level: Current trading right here = point of maximum tension before the data release

Gamma-Based Support & Resistance Analysis

Current Price: $99.80

The gamma exposure map reveals the key price levels market makers are anchored to:

🟠 Resistance Levels (Call Gamma Above Price):

• $100 - Immediate ceiling with 1.49 total GEX (call gamma 0.99 vs put gamma 0.50) - right at current price. This is the first hurdle
• $105 - PRIMARY resistance with 3.04 total GEX (call gamma 2.86 - the DOMINANT level). This is where the option buyer is striking. Massive call positioning here means dealers will sell into rallies approaching $105 - but a clean break above becomes rocket fuel
• $110 - Secondary resistance at 0.73 total GEX
• $115 - Extended ceiling at 0.47 total GEX

🔵 Support Levels (Put Gamma Below Price):

• $95 - Immediate floor with 0.71 total GEX - first line of defense (4.8% below current)
• $90 - Major support at 2.05 total GEX (put gamma 2.00 - dominant put level). This is THE floor the market is defending. A close below $90 would signal serious trouble
• $85 - Secondary support at 0.29 total GEX
• $80 - Deeper floor at 1.78 total GEX (strong put gamma 1.62)

What this means for traders:

RVMD is trading in a tight band between the $95 support floor and the $105 call gamma wall. The net GEX bias is Bullish (total call GEX 7.88 vs total put GEX 5.31), which means market makers are net long delta here - they'll buy dips and potentially let the stock run.

The critical insight: The option buyer struck EXACTLY at $105 where the heaviest call gamma sits. If the Phase 3 data drops positive and the stock gaps through $105, the call gamma squeeze could turbocharge the move - dealers would need to buy stock aggressively to hedge their short call exposure, creating a feedback loop.

Net GEX Bias: Bullish (7.88 call GEX vs 5.31 put GEX)

Implied Move Analysis

Options market current pricing:

The market is pricing ±$3.70 for the March 20 Triple Witch OPEX in just 3 days - a 3.73% expected move. This is SMALL for RVMD.

Why the implied move looks "quiet" right now: Near-term options are not fully capturing the binary Phase 3 risk because the data could drop anywhere in "H1 2026" - the market can't price precision risk across a multi-month uncertainty window into a 3-day expiry. But the April 17 options this trader bought? Those are priced at $8.00 with RVMD at $100.00 - implying about 8% of stock price just for this 31-day window. That's expensive, and it tells you the options market IS pricing in serious binary risk over this horizon.

Key insight: The fact that someone paid $8.00 (8% premium) for 31-day OTM calls signals the market's implied volatility on April options is elevated. They're not getting a bargain - they're paying for a specific thesis: the data lands before April 17 and it's positive.

---

🎪 Catalysts

🔥 IMMINENT Catalyst - The Whole Reason for This Trade

RASolute 302 Phase 3 Top-Line Data - H1 2026 (COULD DROP ANY DAY)

This is the single most important event in RVMD's history. The RASolute 302 trial evaluates daraxonrasib (RMC-6236) as monotherapy in second-line metastatic pancreatic cancer (PDAC) - one of the deadliest cancers with essentially no effective second-line options today.

Critical facts:

• ✅ Enrollment completed February 2026 - the clock is running on OS follow-up
• ✅ OS-powered trial: Looking for a statistically significant improvement in overall survival vs. physician's choice (median ~6 months)
• ✅ Breakthrough Therapy Designation already granted for daraxonrasib in previously-treated PDAC
• ✅ CNPV Voucher in hand: Once NDA filed, FDA review could take 1-2 months instead of 10-12
• 💰 TAM: ~65,000 new PDAC cases/year in the US, $10B+ addressable market at $150-200K annual treatment cost

This is binary in the purest sense:

• 📈 Positive readout: Stock likely gaps 40-80% overnight. NDA filing prep begins immediately. M&A speculation reignites
• 📉 Negative readout: Stock could retrace to $40-60 range (pre-M&A speculation levels)

🚀 Recent Positive Catalysts (Already in the Bank)

• FDA Breakthrough Therapy Designation - Zoldonrasib (January 2026): The second pipeline drug (RMC-9805) got BTD for KRAS G12D NSCLC. Validates the platform even before RASolute 302 reads out
• Piper Sandler raised PT to $120 (February 26, 2026): Fresh analyst upgrade post-Q4 results, Overweight maintained
• Q4 2025 Financial Results (February 25, 2026): Cash position confirmed at $2.03B. Five Phase 3 programs running simultaneously funded
• Baker Bros. Advisors acquired RVMD shares (March 15, 2026): Baker Bros. is THE legendary biotech-specialist fund. When they buy, biotech traders pay attention
• Bellevue Group AG raised position 21.7% and Nextech Invest raised 20.7%: Institutional accumulation continuing post-Merck dip

📅 Upcoming Catalysts (H1-H2 2026)

⚠️ Past Catalysts That Still Weigh

• Merck Acquisition Talks Collapsed (January 23, 2026): Merck was reportedly willing to pay ~$28-30B; talks ended on price. AbbVie was also named as a potential interested party. The M&A overhang is gone but the platform value that attracted Merck remains unchanged
• Q4 2025 Net Loss of $364.9M: Expected for a clinical-stage company in late-stage trials - not a red flag, just context on burn rate. Full-year 2025 loss was $1.13B

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, the RASolute 302 binary, and the April 17 expiration window:

📈 Bull Case (35% probability over 31-day window)

Target: $115-$140

How we get there:

• 💥 RASolute 302 positive top-line data drops before April 17 - stock gaps 30-40% overnight
• 🎯 Clean break above $105 gamma wall triggers dealer-driven short squeeze to $110-$115
• 🏥 AACR 2026 (April 25-30) data presentations provide additional bullish catalyst in the option window
• 📊 JP Morgan $122 price target and analyst consensus of $124.38 get re-rated
• 🤝 M&A speculation reignites with AbbVie or other large pharma post-positive data

The option P&L in this scenario:

• Stock at $120 on April 17: RVMD $105 calls worth ~$15.00+ → profit ~$7/contract, total $3.5M+ gain (125%+ ROI on $2.8M bet)
• Stock at $130 on April 17: Calls worth ~$25.00 → profit ~$17/contract = massive 213% ROI

🎯 Base Case (40% probability)

Target: $95-$105 (Chop City)

Most likely scenario:

• 📅 RASolute 302 data does NOT drop before April 17 - the option buyer is early by a few weeks
• ⚖️ Stock continues to consolidate in the $95-$105 gamma band while waiting for the catalyst
• 📊 Triple Witch OPEX March 20 passes without major directional move (implied ±$3.70)
• 😰 Time decay (theta) destroys value in the calls from $8.00 toward $3-4 as April 17 approaches with no data
• 🔄 Institutional holders wait, stock grinds sideways

The option P&L in this scenario:

• Stock still at $100 on April 17: Calls expire worthless → full $2.8M loss
• The call buyer wins ONLY if the catalyst arrives. No data = no prize.

📉 Bear Case (25% probability)

Target: $75-$90

What could go wrong:

• 😰 RASolute 302 NEGATIVE data drops - stock gaps 40-60% lower overnight, potentially retesting $40-60 range
• 🩸 Even with negative primary endpoint, could temporarily stabilize on secondary endpoint chatter, but institutional selling pressure would be severe
• 💸 Dilution risk materializes - $1B ATM offering weighs on stock as the $90 gamma floor gives way
• ⚖️ Broader biotech/risk-off selloff drags RVMD below $90 gamma support (2.05 total GEX)
• 📉 Break below $90 opens path to $80 (next major put gamma floor at 1.78 total GEX)

Critical support to watch:

• 🛡️ $95: Immediate floor (0.71 total GEX) - first test
• 🛡️ $90: Major support (2.05 total GEX, dominant put gamma) - THE line in the sand
• 🛡️ $80: Deeper floor (1.78 total GEX) - serious damage scenario

---

💡 Trading Ideas

🛡️ Conservative: Wait for the Triple Witch to Clear

Play: Stay in cash on new RVMD positions until after March 20 OPEX

Why this works:

• ⏰ Triple Witch OPEX on March 20 (3 days away) with ±$3.70 implied move could create volatility before the real catalyst
• 💸 April 17 options are already expensive (IV elevated ahead of binary Phase 3 data)
• 🎯 Look to buy the underlying stock on any dip to the $90-$95 gamma support zone if you believe the clinical thesis
• ✅ Owning stock (not options) gives you unlimited time for the RASolute 302 data to arrive - no expiration pressure
• 📊 Analyst consensus $124.38 target with 16 Buy ratings offers long-term upside for patient holders

Expected outcome: Miss the lottery-ticket upside but avoid the total-loss risk of buying time-decaying calls on a catalyst with no confirmed date

Risk level: Minimal (cash or stock) | Skill level: Beginner-friendly

⚖️ Balanced: May Expiration Calls - Buy More Time

Play: Buy the RVMD $110 calls expiring May 15, 2026 instead of the April 17s

Why this works:

• ✅ An extra 4 weeks of time vs. the whale's April 17 trade gives the Phase 3 data more runway to arrive
• 🎯 $110 strike gives you upside exposure above the dominant $105 call gamma resistance level
• ⏰ May expiry also captures AACR/ASCO conference season (April-May) where additional data could be presented
• 📊 Same bullish thesis, less expiration risk if the data is slightly delayed

Estimated trade:

• 💰 Cost: ~$5-6 per contract for May $110 calls (rough estimate)
• 📈 Max profit: Unlimited upside if RASolute 302 positive
• 📉 Max loss: Full premium (accept it's a binary lottery)
• 🎯 Breakeven: ~$115-116 (16% above current price)

Position sizing: Risk ONLY 1-2% of portfolio. This is a binary bet, not a core holding. If you buy 10 contracts, be comfortable losing the entire $5,000-$6,000.

Risk level: Moderate-High (binary, defined risk) | Skill level: Intermediate

🚀 Aggressive: Bull Call Spread - Copy the Whale's Strike, Cut the Cost

Play: Buy $105 calls / Sell $115 calls, April 17 expiration

Why this could work:

• 🎯 Same $105 strike as the institutional buyer, but selling the $115 to reduce cost
• 💸 Net debit roughly $4-5 vs $8 for naked calls = cuts breakeven cost significantly
• 📈 Max profit at $115+ (still captures a solid post-data spike scenario)
• 🎢 Defined max loss (net debit paid) - you know your worst case before entering

Estimated P&L:

• 💰 Cost: ~$4.50 net debit per spread
• 📈 Max profit: ~$5.50 per spread if RVMD above $115 at expiration ($115 - $105 - $4.50 cost)
• 📉 Max loss: $4.50 per spread (debit paid) if RVMD below $105
• 🎯 Breakeven: ~$109.50

Risk level: High (binary, limited upside cap) | Skill level: Intermediate-Advanced

Important caveat: Capping your upside at $115 with a spread means if RASolute 302 is a massive home run and RVMD gaps to $140, you leave significant money on the table vs the naked call buyer. Size accordingly.

---

⚠️ Risk Factors

Don't ignore these before trading RVMD:

• 🧬 RASolute 302 is a make-or-break binary: A miss on the OS primary endpoint would be catastrophic. OS-powered trials in 2L PDAC are historically challenging - the control arm (physician's choice) has median OS ~6 months, and beating that meaningfully is no sure thing. The entire $19.5B valuation rests on this data. A negative readout risks a 40-60% single-day drop
• ⏰ April 17 expiration is a gamble on timing: If the data lands May 1, the April calls are worthless even if the data is great. The whale could be wrong not on direction but on timing - and that's a $2.8M mistake
• 💸 Dilution hangover: RVMD filed a $1.24B shelf registration and announced $1B ATM - potential equity raises could pressure the stock even on good news
• 📊 Insiders net selling: 9 insider sell transactions totaling $8.86M with zero buys in the past 3 months. Management selling doesn't always mean bad news (diversification, tax planning), but it's worth noting when you're considering bullish bets
• 🏦 $1.13B annual burn: Zero product revenue with heavy R&D spend ($294.9M in Q4 2025 alone). The $2.03B cash plus Royalty Pharma support funds through multiple catalysts, but if data fails, the funding picture changes dramatically
• 🔬 No approved KRAS G12X therapies exist yet: This is first-in-class territory. Investors who've watched prior "first-in-class" biotech stories know they don't always work on the first attempt. Amgen's sotorasib required two shots before finding its footing
• 📉 Pre-revenue biotech in rising rate environment: At ~25,000x trailing "sales" (they have none), RVMD is pure sentiment and clinical data. Any macro risk-off move hits names like this disproportionately hard
• 🐋 The $105 call gamma wall is a real obstacle: Before the stock can sprint higher, it needs to clear the heaviest call gamma concentration at $105 (3.04 total GEX). Market makers will systematically sell stock as price approaches - you need a clean catalyst gap to blow through this level

---

🎯 The Bottom Line

Real talk: Someone spent $2.8 million on a 31-day bet that one of the most important Phase 3 readouts in oncology this year drops BEFORE April 17. The RASolute 302 top-line data for daraxonrasib in second-line pancreatic cancer isn't just meaningful for RVMD - it would be the first Phase 3 validation of a RAS(ON) multi-selective inhibitor ever. If it works, it could reshape how we treat the deadliest common cancer.

What this trade is really saying:

• 🎯 The buyer has intelligence - either through channel checks, enrollment timing analysis, or management signals - that this data is imminent, not months away
• 💰 Paying $8.00 (8% of stock price) for 31-day OTM calls is expensive. You do this when you have high conviction on both direction AND timing
• 📊 Striking at EXACTLY $105 - the dominant call gamma level - is deliberate positioning to profit from a potential gamma squeeze if the data gaps through that level
• 🏥 Baker Bros. buying shares March 15 just two days before this options trade is NOT a coincidence worth ignoring

If you're bullish on RVMD:

• ✅ Stock at $95-100 offers meaningful risk/reward IF you can stomach a 40-60% drawdown on a negative Phase 3 readout
• 📊 Analyst consensus at $124.38 with 16 Buys provides standalone fundamental support
• ⏰ Do NOT use near-dated options (April 17) unless you have strong conviction the data lands this month. Timing risk is severe with a binary biotech catalyst
• 🛡️ If entering options, give yourself time: May or June expiry reduces the "right thesis, wrong date" failure mode

If you're watching from sidelines:

• 👀 March 20 Triple Witch OPEX passes in 3 days - watch price action around $95-$105 for signals
• 🎯 Any dip to the $90 gamma support zone (2.05 total GEX) with no new negative news would be a high-risk/reward entry for believers in the clinical thesis
• 📅 AACR Annual Meeting (April 25-30, 2026) is a potential second-tier catalyst window even if Phase 3 data comes slightly after April 17 OPEX

If you're bearish (this is a minority view given analyst consensus):

• ⚠️ Shorting a binary biotech pre-catalyst is extremely dangerous. The upside risk on a positive Phase 3 is massive
• 📉 If you must express a bearish view, use put spreads with limited risk - don't be naked short RVMD

Mark your calendar:

• 📅 March 20, 2026 - Triple Witch OPEX (3 days away - near-term price settlement)
• 📅 H1 2026 (ANYTIME) - RASolute 302 Phase 3 top-line data - THE catalyst
• 📅 April 17, 2026 - Expiration of the $2.8M call trade
• 📅 April 25-30, 2026 - AACR Annual Meeting - potential data presentations
• 📅 H1 2026 - RASolve 308 Phase 3 initiation (zoldonrasib in 1L NSCLC)

Final verdict: The $2.8M call bet on RVMD is one of the more compelling biotech trades we've seen this year because the timing logic is sound. Enrollment completed February 2026, OS data in PDAC typically matures in 3-6 months post-enrollment completion, and the buyer has positioned just one strike above current price for a 31-day window. This is not random speculation - it's a thesis-driven bet on imminent binary news. That said, if you're not comfortable losing 100% of your options premium in a biotech binary, the stock itself (or patient May/June options) gives you the same bullish exposure without the guillotine expiration date.

This is a marathon opportunity wrapped in a sprint-style trade. Know which runner you are before you enter. 🧬

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and is not financial advice. RVMD is a pre-revenue clinical-stage company with binary Phase 3 risk - the stock can move 40-60% in either direction on a single data readout. Options positions can lose 100% of their value. The unusual options activity described may reflect hedging strategies or information not available to the general public. Always do your own research and consult a licensed financial advisor before trading. Past unusual activity in options markets does not guarantee future stock price performance.

---

About Revolution Medicines (RVMD): Revolution Medicines is a clinical-stage oncology company pioneering RAS(ON) multi-selective inhibitors for RAS-driven cancers including pancreatic ductal adenocarcinoma and non-small cell lung cancer. Market cap approximately $19.6 billion in the Biological Products sector with five concurrent Phase 3 clinical programs and $2.03B in cash as of year-end 2025.